sever
fever
thrombocytopenia
syndrom
viru
sftsv
emerg
tickborn
viru
genu
banyangviru
famili
phenuivirida
order
bunyaviral
first
identifi
huaiyangshan
mountain
area
huaiyang
counti
henan
provinc
china
subsequ
viru
also
isol
infect
human
tick
mammal
japan
south
korea
sftsv
name
caus
sever
fever
thrombocytopenia
syndrom
sft
acut
febril
ill
character
high
fever
thrombocytopenia
hemorrhag
complic
infect
human
patient
sft
may
also
develop
clinic
manifest
system
upset
coma
slur
speech
gastrointestin
upset
hepatosplenomegali
lymphadenopathi
well
abnorm
laboratori
find
includ
leukopenia
prolong
activ
partial
thromboplastin
time
derang
liver
function
test
proteinuria
hematuria
elev
creatinin
kinas
lactat
dehydrogen
level
mortal
rate
sft
may
high
addit
tickborn
transmiss
nonvectorborn
transmiss
sftsv
also
report
number
case
cluster
link
nosocomi
intrafamili
transmiss
describ
major
secondari
case
cluster
like
infect
unprotect
direct
contact
index
patient
blood
andor
bodili
fluid
high
viral
load
possibl
transmiss
viru
exposur
contamin
hospit
environ
surfac
aerosol
also
report
recent
despit
clinic
public
health
import
sftsv
treatment
option
remain
limit
ribavirin
exhibit
inhibitori
effect
sftsv
replic
vitro
type
interferon
receptordefici
mous
model
found
effect
retrospect
cohort
patient
compar
favipiravir
rnadepend
rna
polymeras
inhibitor
broadspectrum
antivir
activ
demonstr
higher
vitro
vivo
antivir
effect
sftsv
howev
favipiravir
clinic
approv
readili
avail
mani
countri
affect
sftsv
includ
china
identifi
drug
compound
use
treat
patient
reduc
transmiss
sftsv
especi
hospit
set
conduct
drug
repurpos
program
screen
food
drug
administr
fda
approv
drug
librari
consist
drug
compound
first
establish
robust
twotier
elisa
follow
viral
load
reduct
assay
screen
platform
sftsv
use
drug
screen
platform
identifi
five
drug
compound
antisftsv
activ
vitro
character
antisftsv
mechan
potent
drug
hexachlorophen
entri
inhibitor
sftsv
sftsv
strain
gift
dr
benjamin
brennan
mrcunivers
glasgow
centr
viru
research
professor
mifang
liang
china
cdc
propag
vero
cell
kept
aliquot
plaqu
form
unit
pfu
assay
perform
titrat
cultur
viru
vero
african
green
monkey
kidney
atcc
human
hepatoma
jcrb
cell
maintain
dulbecco
modifi
eagl
medium
dmem
gibco
ca
usa
cultur
medium
supplement
heatinactiv
fb
fetal
bovin
serum
gibco
uml
penicillin
streptomycin
previous
describ
upon
viru
infect
cell
maintain
fbsfree
medium
without
drug
compound
experi
involv
live
sftsv
follow
approv
standard
oper
procedur
biosafeti
level
facil
depart
microbiolog
univers
hong
kong
fdaapprov
drug
librari
cat
test
drug
compound
purchas
medchem
express
monmouth
junction
nj
usa
unless
otherwis
specifi
celltiterglo
luminesc
assay
promega
corpor
madison
wi
usa
perform
detect
cytotox
select
drug
compound
previous
describ
briefli
vero
cell
cellswel
incub
differ
concentr
individu
compound
h
follow
addit
substrat
measur
lumin
min
later
cytotox
concentr
drug
calcul
sigma
plot
spss
excel
addin
explor
suitabl
assay
fdaapprov
drug
librari
screen
cytopath
effect
cpe
inhibit
assay
also
perform
previous
describ
slight
modif
briefli
vero
cell
seed
plate
infect
sftsv
h
differ
multipl
infect
moi
follow
phosphat
buffer
salin
pb
wash
replac
fresh
dmem
medium
contain
dmso
neg
control
favipiravir
posit
control
cell
viabil
well
determin
day
postinfect
dpi
celltiterglo
luminesc
assay
elisa
perform
determin
amount
viral
nucleoprotein
np
express
cultur
supernat
previous
describ
modif
briefli
ngwell
rabbitantisftsv
serum
cat
abnova
taipei
citi
taiwan
coat
elisa
plate
overnight
incub
follow
block
fb
plu
fb
pb
tween
sigmaaldrich
st
loui
mo
usa
h
wash
cultur
supernat
collect
dpi
transfer
elisa
plate
accordingli
incub
room
temperatur
h
follow
intens
wash
addit
mouseantisftsvnp
serum
inhous
prepar
secondari
goatantimous
horseradish
peroxidas
hrp
antibodi
invitrogen
carlsbad
ca
usa
tmb
solut
invitrogen
stop
solut
hcl
subsequ
optic
densiti
well
read
nm
use
victor
multilabel
plate
reader
perkinelm
inc
waltham
usa
viral
load
reduct
assay
perform
describ
previous
modif
briefli
viru
infect
drug
treatment
first
perform
describ
cpe
inhibit
assay
cultur
supernat
collect
dpi
follow
total
nucleic
acid
extract
quantit
revers
transcriptionpolymeras
chain
reaction
qrtpcr
previous
establish
primer
forward
revers
tgccttcaccaagactatcaatgt
probe
fitcttctgtcttgctggctccgcgcbhq
target
segment
sftsv
genom
perform
use
roch
lightcycl
realtim
pcr
system
plaqu
reduct
assay
perform
describ
previous
modif
briefli
vero
cell
seed
cellswel
tissu
cultur
plate
day
assay
perform
h
incub
pfu
sftsv
ad
cell
monolay
without
addit
select
drug
compound
plate
incub
h
remov
unbound
viral
particl
aspir
media
wash
dmem
cell
monolay
overlaid
media
contain
low
melt
agaros
cambrex
corpor
east
rutherford
nj
usa
appropri
concentr
drug
compound
invert
incub
state
anoth
day
next
well
fix
formaldehyd
bdh
merck
darmstadt
germani
overnight
remov
agaros
plug
cell
monolay
stain
crystal
violet
bdh
merck
number
plaqu
count
percentag
plaqu
inhibit
rel
control
ie
without
addit
drug
compound
well
determin
drug
concentr
half
maxim
inhibitori
concentr
calcul
use
sigma
plot
spss
excel
addin
determin
hexachlorophen
inhibit
cell
membran
fusion
sftsv
syncytium
format
virusinfect
cell
determin
lowph
exposur
previous
describ
briefli
vero
cell
infect
sftsv
moi
hpi
cell
rins
pb
incub
citratephosph
buffer
citric
acid
sodium
dihydrogen
orthophosph
sigmaaldrich
st
loui
mo
usa
adjust
ph
min
citratephosph
buffer
replac
without
hexachlorophen
treatment
h
cell
fusion
within
monolay
observ
phasecontrast
microscop
structur
hexachlorophen
id
code
download
drugbank
databas
http
wwwdrugbankca
crystal
structur
sftsv
gc
protein
pdb
code
use
build
dock
receptor
bond
order
assign
hydrogen
ad
cap
termini
includ
protein
prepar
wizard
modul
implement
maestro
proton
state
side
chain
predict
use
server
partial
charg
atom
final
assign
within
forc
field
scheme
implement
ambertool
ligand
bind
site
predict
server
ligandreceptor
dock
perform
leadfind
version
toprank
pose
visual
pymol
intermolecular
interact
visual
ligplot
establish
sensit
assay
antisftsv
drug
screen
compar
signal
dynam
rang
screen
window
three
assay
ie
cpe
inhibit
assay
elisa
viral
load
reduct
assay
cell
viabil
sftsvnp
protein
express
ssegment
viral
genom
copi
number
cultur
supernat
monitor
dpi
respect
favipiravir
use
posit
control
three
assay
shown
figur
differ
cell
viabil
favipiravirtr
dmsotreat
group
less
indic
cpe
inhibit
assay
sensit
assay
drug
screen
favipiravir
use
posit
control
next
cultur
supernat
subject
elisa
qrtpcr
analys
shown
figur
readout
favipiravirtr
dmsotreat
group
detect
moi
dpi
dpi
respect
elisa
viral
load
reduct
assay
approxim
differ
sftsv
rna
load
two
group
dpi
dpi
figur
data
suggest
elisa
viral
load
reduct
assay
sensit
drug
screen
assay
sftsv
consid
costeffect
two
assay
need
balanc
maximum
drug
efficaci
drug
halflif
drug
compound
librari
screen
perform
use
elisa
moi
sftsv
viru
inoculum
cultur
supernat
collect
dpi
fdaapprov
drug
librari
drug
compound
screen
use
optim
condit
concentr
drug
set
elisa
util
primari
screen
follow
viral
reduct
assay
secondari
valid
assay
among
drug
compound
top
primari
hit
reduct
absorb
signal
elisa
subject
viral
load
reduct
assay
fix
drug
compound
concentr
select
compound
inhibit
sftsv
replic
dosedepend
manner
drug
compound
obviou
cytotox
exclud
five
drug
compound
name
hexachlorophen
triclosan
regorafenib
eltrombopag
broxyquinolin
identifi
antisftsv
drug
compound
twostep
screen
figur
five
drug
compound
priorit
antivir
potenc
ie
tabl
hexachlorophen
select
character
lowest
highest
select
index
among
five
drug
compound
viral
load
reduct
assay
antisftsv
activ
hexachlorophen
valid
viral
load
reduct
assay
differ
cell
line
plaqu
reduct
assay
dosedepend
reduct
viral
rna
load
observ
cultur
supernat
hexachlorophenetr
vero
cell
figur
hexachlorophen
reduc
viral
rna
load
hpi
plaqu
reduct
assay
hexachlorophen
achiev
plaqu
reduct
figur
absenc
sftsv
infect
hexachlorophen
exhibit
hpi
vero
cell
figur
differenti
whether
entri
postentri
phase
sftsv
replic
cycl
interrupt
hexachlorophen
perform
viru
entri
assay
expos
sftsvinfect
cell
hexachlorophen
viru
entri
step
follow
quantif
intracellular
sftsv
viral
rna
load
hpi
shown
figur
hexachlorophen
dmso
comix
sftsv
moi
incub
vero
cell
h
significantli
lower
viral
rna
load
detect
cell
comix
hexachlorophen
p
comix
dmso
expectedli
statist
signific
differ
dmso
favipiravir
group
latter
viral
polymeras
inhibitor
figur
result
indic
hexachlorophen
treatment
interf
sftsv
entri
dissect
antisftsv
mechan
hexachlorophen
perform
viru
attach
inactiv
assay
investig
whether
drug
inhibit
viru
attach
host
cell
surfac
directli
inactiv
viral
particl
bind
viral
envelop
shown
figur
signific
p
inhibitori
activ
observ
hexachlorophen
ad
vero
cell
pretreat
drug
compound
hpi
suggest
viru
attach
host
cell
surfac
affect
viru
infect
also
significantli
p
impair
sftsv
preincub
hexachlorophen
h
follow
detect
plaqu
format
hexachlorophen
concentr
figur
fusion
virusinfect
cell
neighbor
cell
lead
format
multinucl
enlarg
cell
syncytia
event
induc
surfac
express
viral
fusion
protein
fusogen
directli
host
cell
membran
virus
abl
directli
fuse
cellular
surfac
without
need
endocytosi
induc
syncytium
format
syncytium
format
sftsvinfect
cell
trigger
low
ph
buffer
sinc
hexachlorophen
interf
sftsv
entri
without
inhibit
viral
attach
host
cell
inactiv
virion
figur
therefor
ask
hexachlorophen
inhibit
sftsv
membran
fusion
end
first
treat
sftsvinfect
cell
citratephosph
buffer
adjust
ph
cell
treat
hexachlorophen
figur
shown
figur
syncytium
format
sftsvinfect
cell
dramat
inhibit
hexachlorophen
dosedepend
manner
indic
sftsvinduc
cell
fusion
impair
viral
envelop
protein
known
fuse
plasma
endosom
membran
allow
releas
viral
genom
sftsv
segment
encod
two
viral
envelop
glycoprotein
gp
gn
gc
ntermin
gn
respons
receptor
bind
cell
surfac
ctermin
gc
fusion
protein
facilit
viru
entri
character
rel
bind
affin
intermolecular
interact
hexachlorophen
sftsv
gc
glycoprotein
molecular
dock
perform
predict
bind
pose
drug
shown
figur
hexachlorophen
predict
bind
deep
hydrophob
pocket
domain
domain
iii
sftsv
gc
glycoprotein
rel
bind
free
energi
output
kcalmol
broad
area
hydrophob
interact
ligand
protein
predict
occur
hydrogen
halogen
bond
predict
stabil
bind
pose
figur
c
overal
find
suggest
bind
hexachlorophen
hydrophob
pocket
sftsv
gc
glycoprotein
highli
stabl
exemplifi
recent
epidem
caus
sever
acut
respiratori
syndrom
middl
east
respiratori
syndrom
coronavirus
ebola
viru
zika
viru
de
novo
develop
new
antivir
treatment
invari
lag
behind
rapid
progress
emerg
viral
outbreak
thu
drug
repurpos
program
increasingli
conduct
find
clinic
approv
drug
vitro
andor
vivo
activ
emerg
virus
candid
drug
compound
identifi
drug
repurpos
program
advantag
clinic
avail
known
pharmacokinet
pharmacodynam
side
effect
profil
inform
would
facilit
rapid
develop
repurpos
drug
compound
clinic
use
sftsv
emerg
tickborn
bunyaviru
caus
sever
diseas
infect
human
limit
antivir
treatment
option
studi
establish
robust
twotier
drug
screen
platform
use
screen
drug
librari
consist
fdaapprov
drug
compound
success
identifi
five
drug
abl
inhibit
sftsv
replic
low
micromolar
level
includ
antibacteri
antifung
disinfect
hexachlorophen
triclosan
multikinas
inhibitor
treatment
advanc
solid
organ
tumor
regorafenib
small
molecul
agonist
cmpl
receptor
treatment
immun
thrombocytopen
purpura
aplast
anemia
eltrombopag
antiprotozo
agent
broxyquinolin
among
five
drug
hexachlorophen
demonstr
highest
antivir
potenc
vitro
hexachlorophen
organochlorin
compound
wide
use
topic
antibacteri
antifung
disinfect
surgic
scrub
well
agricultur
bactericid
fungicid
pesticid
moreov
hexachlorophen
also
exhibit
antivir
activ
variou
rna
dna
virus
disinfect
contain
hexachlorophen
exhibit
antivir
activ
rhinoviru
combin
ethyl
alcohol
rotaviru
hexachlorophen
hexachlorophen
isopropylalcohol
hexachlorophen
inhibit
proteas
activ
sever
acut
respiratori
syndrom
coronaviru
vitro
replic
coronavirus
includ
murin
hepat
viru
bovin
coronaviru
human
enter
coronaviru
hexachlorophen
also
exhibit
antivir
activ
polyomavirus
bk
viru
simian
viru
inhibit
larg
tumor
antigen
atpas
activ
virus
present
studi
expand
spectrum
antivir
activ
describ
novel
antivir
mechan
hexachlorophen
show
hexachlorophen
potent
inhibit
sftsv
replic
evidenc
signific
reduct
viral
rna
load
plaqu
reduct
drug
concentr
hexachlorophen
sftsv
lower
antisftsv
drug
compound
report
thu
far
caffeic
acid
ribavirin
favipiravir
amodiaquin
use
combin
viru
entri
attach
inactiv
membran
fusion
assay
show
hexachlorophen
interf
viru
entri
virusinduc
cell
fusion
without
affect
viru
attach
host
cell
inactiv
virion
molecular
dock
predict
hexachlorophen
bound
stabli
deep
hydrophob
pocket
domain
domain
iii
sftsv
gc
glycoprotein
provid
insight
structur
interact
hexachlorophen
sftsv
explain
drug
vitro
antivir
activ
novel
find
studi
number
import
implic
first
show
twotier
drug
screen
platform
robust
system
util
identifi
antisftsv
drug
compound
rapidli
system
could
use
screen
larger
chemic
librari
contain
drug
compound
find
addit
treatment
option
sftsv
second
novel
antivir
activ
mechan
hexachlorophen
studi
would
facilit
use
hexachlorophen
lead
compound
develop
entri
inhibitor
higher
antisftsv
potenc
lower
toxic
antivir
activ
mechan
identifi
hit
compound
twotier
screen
system
character
futur
studi
final
use
hexachlorophen
disinfect
consid
reduc
risk
nosocomi
outbreak
sftsv
associ
contamin
environment
surfac
